David P Meeker
CIK 1385155 · President and CEO · last filed 2026-06-04
David P Meeker is a President and CEO who has filed 53 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for TRVI, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$7.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $33.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$33.64M
6
53
-$7.22M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Director | 685,012 | $14.21 | $9.73M | $99.1K | 11 | 2026-06-04 |
| RYTM | President and CEO | 270,538 | $88.38 | $23.91M | -$5.01M | 17 | 2026-02-13 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 2,300 | — | — | $0 | 7 | 2020-06-23 |
| SAVIENT PHARMACEUTICALS INC (SVNT) Delisted | Director | 12,644 | — | — | $0 | 1 | 2013-01-17 |
| GENZYME CORP (GENZ) Delisted | ExecVP,Chief Operating Officer | 0 | — | — | -$2.31M | 8 | 2011-04-06 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | Director | 0 | — | — | $0 | 8 | 2010-09-22 |
Recent Filings
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2026-02-13 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2026-02-03 | RYTM | Mixed | +37,191 | -$3.44M | EDGAR |
| 2025-06-13 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | RYTM | Mixed | — | -$2.64M | EDGAR |
| 2025-02-19 | RYTM | Mixed | +11,354 | -$566.2K | EDGAR |
| 2025-02-04 | RYTM | Mixed | +9,847 | -$254.2K | EDGAR |
| 2024-08-29 | TRVI | Mixed | — | -$6.8K | EDGAR |
| 2024-06-14 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2024-03-19 | RYTM | Sell (S) | −45,494 | -$1.78M | EDGAR |